NCT05223335View on ClinicalTrials.gov

Clopidogrel Monotherapy in Patients With High Bleeding Risk

PHASE4CompletedINTERVENTIONAL

Enrollment

98

Participants

Timeline

Start Date

March 29, 2022

Primary Completion Date

March 16, 2023

Study Completion Date

March 16, 2023

Conditions

Bleeding Complications

Interventions

DRUG

Clopidogrel

75 mg/day

DRUG

Prasugrel

60 mg bolus then 10 mg daily

DRUG

Tricagrelor

180 mg bolus then 90 mg twice daily

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mayo Clinic

OTHER

NCT05223335 - Clopidogrel Monotherapy in Patients With High Bleeding Risk | Biotech Hunter | Biotech Hunter